My best guessSo, this financing takes care of the convert ($60 million drawn down by 6/23). But it does not provide funding for any early phase II cancer trials. So, we could still see some equity issuance if TH-1902 does well in phase 1b, which should come at a higher price if TH-1902 shows promise. if not, and it needs to be retooled first, then there may be no need to raise new funds as Egrifta sales are going well and they likely have a 95% gross margin on them, which should provide a lot of money to run the normal operations ex new clinical trials.